Insider buying
~$29K21K sh @ $1.40
Traded Apr 30, 2025 · filed the same day
A Zentalis Pharmaceuticals director paid $29K out of pocket for Zentalis Pharmaceuticals shares. Shares held went up 8% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ZNTL · NASDAQ · Pharmaceutical Preparations
Zentalis Pharmaceuticals (ZNTL) · oqro.io/stocks/ZNTL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.36+0.00 (0.00%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
1 routine filing (option exercises, shares withheld for taxes, grants, gifts) is not listed here. Show them
Insider buying
Traded Apr 30, 2025 · filed the same day
A Zentalis Pharmaceuticals director paid $29K out of pocket for Zentalis Pharmaceuticals shares. Shares held went up 8% with this purchase.
Insider buying
Traded Feb 6, 2025 · filed 6 days later
Zentalis Pharmaceuticals's Chief Medical Officer paid $46K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 120% with this purchase.
Mark Lackner (Chief Scientific Officer) sold ~$25K of Zentalis Pharmaceuticals
Automatic saleAndrea Paul (Chief Legal Officer) sold ~$23K of Zentalis Pharmaceuticals
Automatic saleVincent Vultaggio (PAO and Interim PFO) sold ~$4.5K of Zentalis Pharmaceuticals
Automatic saleInsider buying
Traded Jan 31, 2025 · filed 4 days later
A Zentalis Pharmaceuticals director paid $103K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 67% with this purchase.
Insider buying
Traded Jan 31, 2025 · filed 4 days later
A Zentalis Pharmaceuticals director paid $25K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 20% with this purchase.
Insider buying
Traded Jan 31, 2025 · filed 4 days later
The CEO of Zentalis Pharmaceuticals paid $49K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month.
Mark Lackner (Chief Scientific Officer) sold ~$14K of Zentalis Pharmaceuticals
Automatic saleVincent Vultaggio (Principal Accounting Officer) sold ~$5.1K of Zentalis Pharmaceuticals
Planned sale0 open-market purchases and 0 open-market sales by insiders of ZNTL between Feb 24, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 9, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 9, 2026 | None | None | None |
| Aug 6, 2026 | None | None | None |
| May 12, 2026 | None | None | None |
| Mar 26, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies